| Literature DB >> 26106329 |
Abstract
Understanding drug transportation mechanisms in the human body is of paramount importance in modeling Pharmacokinetic-Pharmacodynamic relationships. This work gives a novel general model of efavirenz transportation projections based on concentrations simulated from patients on a dose of 600 mg. The work puts forward a proposition that transportation can wholly be modeled by concentration and time in a uniform volumetric space. Furthermore, movement entities are used to inform the state of "kinetic solubility" of a solution. There is use of Ricker's model, and forms of the Hill's equation in modeling transportation. Characterization on the movement rates of solution particle are suggested in relation to advection rate of solution particle. At turning points on the transportation rate of solution particle vs. concentration curve, a suggestion of possibly change of dominance in the mode of transportation and saturation is made. There are four movement rates postulated at primary micro-level transportation, that are attributed to convection, diffusion [passive transportation (EI )] and energy dependent system transportation (ED ) in relation to advection. Furthermore, a new parameter is introduced which is defined as an advection rate constant of solution particle. It is postulated to be dependent on two rate constants of solution particle, that is a convection rate constant of solution particle and a saturable transportation rate constant of solution particle. At secondary micro-level transportation, the results show convection as sum of advection and saturable transportation. The kinetics of dissolution of efavirenz in the solution space is postulated. Relatively, a good level of kinetics of dissolution is projected in the concentration region 0 - 32.82 μg/ml.Entities:
Keywords: advection rate; advection rate constant; convection rate; efavirenz; kinetic solubility; models; passive transportation and energy dependent transportation rate
Year: 2015 PMID: 26106329 PMCID: PMC4458577 DOI: 10.3389/fphar.2015.00121
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Parameter estimates in modeling movement rates in Equation (2).
| −0.0561 | 0.0057 | −9.764 | 5.18× 10−10 | |
| 7.4315 | 0.6922 | 10.737 | 7.49×10−11 | |
| 0.0089 | 0.0003 | 32.289 | < 2 × 10−16 | |
| 0.0598 | 0.0015 | 39.930 | < 2 × 10−16 | |
| 0.8808 | 0.0874 | 10.076 | 2.75×10−10 | |
| 0.0034 | 0.0002 | 14.010 | 2.43×10−13 |
Figure 1The model fit of advection rate .
Parameter estimates in modeling movement rate constants of solution particle for Equation (4).
| ζ | 0.1440 | 0.0040 | 35.69 | < 2 × 10−16 |
| λ | 0.0596 | 0.0007 | 79.89 | < 2 × 10−16 |
| α | −0.7427 | 0.0555 | −13.38 | 3.59 × 10−13 |
| ω | 1.1477 | 0.0123 | 92.98 | <2 × 10−16 |
| κ = ηω | 6.071 | 0.2638 | 23.02 | < 2 × 10−16 |
Figure 2The projected points (produced from Equation 4) of efavirenz plasma concentration (.
Parameter estimates in modeling convection rate constants of solution particle for Equation (5).
| 0.332908 | 0.006517 | 51.08 | < 2 × 10−16 | |
| 0.340341 | 0.010495 | 32.43 | < 2 × 10−16 | |
| 0.032229 | 0.001198 | 26.89 | < 2 × 10−16 |
Figure 3The projected plasma concentration of patient .